2000
DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS
OBIEZU C, GILTAY E, MAGKLARA A, SCORILAS A, GOOREN L, YU H, DIAMANDIS E. DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal Of Urology 2000, 163: 802. DOI: 10.1097/00005392-200003000-00023.Peer-Reviewed Original ResearchUrinary prostate specific antigenProstate-specific antigenCyproterone acetateHormonal therapySpecific antigenFemale transsexualsSensitive immunofluorometric procedureUrine samplesMonths of therapyMonths of treatmentInitiation of treatmentCyproterone acetate therapyProstate cancer treatmentHK2 concentrationsTransdermal estradiolAcetate therapyTumor burdenAntiandrogen treatmentSteroidal antiandrogenAndrogen receptorProstate cancerEthinyl estradiolStudy groupPatient's bloodTherapy success
1999
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma
Diamandis E, Helle S, Yu H, Melegos D, Lundgren S, Lonning P. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999, 85: 891-898. PMID: 10091767, DOI: 10.1002/(sici)1097-0142(19990215)85:4<891::aid-cncr17>3.0.co;2-k.Peer-Reviewed Original ResearchConceptsPlasma prostate-specific antigenProstate-specific antigenPlasma PSA levelsMetastatic breast carcinomaMegestrol acetatePSA levelsPSA increaseMA treatmentPrognostic valueBreast carcinomaSpecific antigenSecretion of PSAMegestrol acetate treatmentPlasma PSA concentrationProgestin megestrol acetateSensitive immunofluorometric procedureSerial plasma levelsSubset of patientsOverall patient survivalRisk of deathMA withdrawalAlternative regimensPSA changeBetter prognosisDistant metastasis
1995
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsProstate-specific antigen immunoreactivity in amniotic fluid.
Yu H, Diamandis E. Prostate-specific antigen immunoreactivity in amniotic fluid. Clinical Chemistry 1995, 41: 204-210. PMID: 7533063, DOI: 10.1093/clinchem/41.2.204.Peer-Reviewed Original ResearchConceptsProtease prostate-specific antigenAmniotic fluidAlpha-fetoproteinGestational ageProstate-specific antigen immunoreactivitySensitive immunofluorometric procedureHigh alpha-fetoproteinHigher PSA concentrationsProstate-specific antigenNormal fetal developmentGrowth factor regulatorSerine protease prostate-specific antigenNonpregnant womenMaternal serumPregnant womenAntigen immunoreactivityBreast tumorsFetal developmentPSA concentrationImmunofluorometric procedurePregnancySignificant correlationWomenAgeSyndrome
1994
Detection of prostate-specific antigen immunoreactivity in breast tumors
Diamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPSA immunoreactivityProgesterone receptorP53 tumor suppressor gene productBreast tumorsProstate-specific antigen immunoreactivitySeminal prostate-specific antigenProgesterone receptor-positive tumorsSensitive immunofluorometric procedureReceptor-positive tumorsEarly disease stagesTumor suppressor gene productBreast tumor extractsSuppressor gene productWestern blot analysisDisease stageProstate carcinomaAntigen immunoreactivityTumor extractsTumor specimensClinical practiceImmunoreactivityTumorsYoung womenImmunofluorometric procedure